Neurological Surgery 脳神経外科49巻3号

2021年05月発行

特集 グリオーマ—現在の常識と近未来のスタンダード Ⅰ知っておくべきグリオーマの生物学的基礎知識

グリオーマのゲノム・エピゲノム異常

著者： 大場茂生¹

所属機関： ¹藤田医科大学医学部脳神経外科学講座

ページ範囲：P.466 - P.475

Point
・グリオーマの発生にはさまざまなゲノム・エピゲノムの異常が関与している．
・ゲノム・エピゲノム異常には診断マーカーや予後因子，予測因子として有用なものも多く含まれる．

参考文献

1）Louis DN, et al：The 2016 World Health Organization Classification of Tumors of the Central Nervous System：a summary. Acta Neuropathol 131：803-820, 2016

2）Ohba S, Hirose Y：Biological significance of mutant isocitrate dehydrogenase 1 and 2 in gliomagenesis. Neurol Med Chir（Tokyo）56：170-179, 2016

3）Parsons DW, et al：An integrated genomic analysis of human glioblastoma multiforme. Science 321（5897）：1807-1812, 2008

4）Yan H, et al：IDH1 and IDH2 mutations in gliomas. N Engl J Med 360：765-773, 2009

5）Hartmann C, et al：Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age：a study of 1,010 diffuse gliomas. Acta Neuropathol 118：469-474, 2009

6）Koivunen P, et al：Transformation by the R enantiomer of 2-hydroxyglutarate linked to EglN activation. Nature 483（7390）：484-488, 2012

7）Ohba S, et al：Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance. Cancer Res 74：4836-4844, 2014

8）Ohba S, et al：Mutant IDH1 expression drives TERT promoter reactivation as part of the cellular transformation process. Cancer Res 76：6680-6689, 2016

9）Philip B, et al：Mutant IDH1 promotes glioma formation in vivo. Cell Rep 23：1553-1564, 2018

10）Reifenberger J, et al：Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145：1175-1190, 1994

11）Jenkins RB, et al：A t（1;19）（q10;p10）mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66：9852-9861, 2006

12）Cairncross JG, et al：Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90：1473-1479, 1998

13）Bettegowda C, et al：Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333（6048）：1453-1455, 2011

14）Monti P, et al：Heterogeneity of TP53 mutations and P53 protein residual function in cancer：does it matter? Front Oncol 10：593383, 2020

15）Finlay CA, et al：Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8：531-539, 1988

16）Bodnar AG, et al：Extension of life-span by introduction of telomerase into normal human cells. Science 279（5349）：349-352, 1998

17）Ohba S, et al：Correlation between IDH, ATRX, and TERT promoter mutations in glioma. Brain Tumor Pathol 37：33-40, 2020

18）Pekmezci M, et al：Adult infltrating gliomas with WHO 2016 integrated diagnosis：additional prognostic roles of ATRX and TERT. Acta Neuropathol 133：1001-1016, 2017

19）Kikuchi Z, et al：TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma. Neurooncol Adv 2：vdaa114, 2020

20）Arita H, et al：TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. Acta Neuropathol Commun 23：201, 2020

21）Sommer A, Royle NJ：ALT：a multi-faceted phenomenon. Genes（Basel）11：133, 2020

22）Fan HC, et al：Targeting telomerase and ATRX/DAXX inducing tumor senescence and apoptosis in the malignant glioma. Int J Mol Sci 20：200, 2019

23）Louis DN, et al：cIMPACT-NOW update 2：diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol 135：639-642, 2018

）in cancer. EBioMedicine 8：30-39, 2016

25）Schmidt EE, et al：CDKN2（p16/MTS1）gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54：6321-6324, 1994

26）Shirahata M, et al：Novel, improved grading system（s）for IDH-mutant astrocytic gliomas. Acta Neuropathol 136：153-166, 2018

27）Brat DJ, et al：cIMPACT-NOW update 5：recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 139：603-608, 2020

28）Brennan CW, et al；TCGA Research Network：The somatic genomic landscape of glioblastoma. Cell 155：462-477, 2013

29）Khani P, et al：Genetic and epigenetic contribution to astrocytic gliomas pathogenesis. J Neurochem 148：188-203, 2019

30）Verhaak RG, et al；Cancer Genome Atlas Research Network：Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17：98-110, 2010

31）Noushmehr H, et al；Cancer Genome Atlas Research Network：Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17：510-522, 2010

32）Patel AP, et al：Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344（6190）：1396-1401, 2014

33）Wiltshire RN, et al：Comparative genetic patterns of glioblastoma multiforme：potential diagnostic tool for tumor classification. Neuro Oncol 2：164-173, 2000

34）Brat DJ, et al：cIMPACT-NOW update 3：recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade Ⅳ”. Acta Neuropathol 136：805-810, 2018

35）Louis DN, et al：cIMPACT-NOW update 6：new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol 30：844-856, 2020

36）Maraka S, Janku F：BRAF alterations in primary brain tumors. Discov Med 26：51-60, 2018

37）Zhang J, et al；St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project：Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45：602-612, 2013

mutation. Acta Neuropathol 137：683-687, 2019

39）Reiter-Brennan C, et al：The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas. Contemp Oncol（Pozn）22：215-222, 2018

40）Schwartzentruber J, et al：Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482（7384）：226-231, 2012

41）Wu G, et al；St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project：Somatic histone H3 alterations in paediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44：251-253, 2012

42）Sturm D, et al：Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22：425-437, 2012

43）Graham MS, Mellinghoff IK：Histone-mutant glioma：molecular mechanisms, preclinical models, and implications for therapy. Int J Mol Sci 21：7193, 2020

44）Hashizume R：Epigenetic targeted therapy for diffuse intrinsic pontine glioma. Neurol Med Chir（Tokyo）57：331-342, 2017

45）Mohammad F, et al：EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat Med 23：483-492, 2017

46）Piunti A, et al：Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med 23：493-500, 2017

47）Stafford JM, et al：Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma. Sci Adv 4：eaau5935, 2018

48）Gessi M, et al：Evidence of H3 K27M mutations in posterior fossa ependymomas. Acta Neuropathol 132：635-637, 2016

49）Kaina B, Christmann M：DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas. DNA Repair（Amst）78：128-141, 2019

50）Hegi ME, et al：MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352：997-1003, 2005

51）Arita H, et al：A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun 4：79, 2016

52）Bhandari AP, et al：Noninvasive determination of IDH and 1p19q status of lower-grade gliomas using MRI radiomics：a systematic review. AJNR Am J Neuroradiol 42：94-101, 2021

53）Mellinghoff IK, et al：Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma. J Clin Oncol 38：3398-3406, 2020